Literature DB >> 35121858

Third COVID-19 jab benefits people with MS.

Sarah Lemprière1.   

Abstract

Entities:  

Year:  2022        PMID： 35121858      PMCID： PMC8815017          DOI： 10.1038/s41582-022-00625-w

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   44.711


× No keyword cloud information.
  1 in total

1.  Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.

Authors:  Marton König; Hilde Marie Torgauten; The Trung Tran; Trygve Holmøy; John Torgils Vaage; Fridtjof Lund-Johansen; Gro Owren Nygaard
Journal:  JAMA Neurol       Date:  2022-03-01       Impact factor: 18.302
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.